CD4 and acute myeloid leukemia: This baseline inflammatory signature disappears after infusion of nivolumab, and the clinical responses are characterized by the temporary expansion of polyclonal CD4+ T-cell populations, the contraction of AML subsets exhibiting megakaryocytic characteristics, and elevated PD-L1 expression (111).